Number of suitable people: CDEC talked over the uncertainty in the quantity of clients with reasonably critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical gurus consulted by CADTH indicated that some people who will be labeled as getting mild or average disorder could possibly have a significant bleeding phe